share_log

Immuneering | 8-K: Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic

Immuneering | 8-K: Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic

Immuneering | 8-K:Immuneering公布2024年第三季度财务业绩并提供最新业务——公布了积极的初步数据,包括完全和部分反应,IMM-1-104与一线胰腺癌患者联合化疗-
美股SEC公告 ·  2024/11/13 16:08
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息